VarmX announced its partnership with CSL, supporting the development of its lead asset VMX-C001, along with entering into an ...

A West Yorkshire initiative is set to accelerate health and wellbeing product development. The Huddersfield Health Innovation ...

As per DelveInsight’s assessment, globally, Chronic Lower Back Pain pipeline constitutes 10+ key companies continuously ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral ...